Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 1/20 | 0.35 |
| ▸ | MARS1 | P56192 | 2/20 | 0.33 |
| ▸ | FNTA | P49354 | 4/20 | 0.32 |
| ▸ | FNTB | P49356 | 4/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.32 |
| ▸ | CTSC | P53634 | 2/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | TACR3 | P29371 | 1/20 | 0.31 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29045686 | 0.88 | ANPEP (0.41) | ANPEPRNPEPDNPEPLTA4HLARS1 | |
| SCHEMBL4398840 | 0.87 | ANPEP (0.38) | ANPEPRNPEPDNPEPLTA4HLARS1 | |
| SCHEMBL1128048 | 0.84 | ANPEP (0.50) | ANPEPRNPEPDNPEPKRASFNTA | |
| Acetic Acid SCHEMBL15201184 | 0.83 | ANPEP (0.48) | ANPEPRNPEPDNPEPKRASFNTA | |
| SCHEMBL9387444 | 0.80 | ANPEP (0.39) | ANPEPRNPEPDNPEPLTA4HLARS1 | |
| SCHEMBL7031217 | 0.79 | MARS1 (0.36) | KRASMARS1FNTAFNTBPGGT1B | |
| SCHEMBL154435 | 0.77 | FNTA (0.34) | ANPEPRNPEPDNPEPKRASMARS1 | |
| SCHEMBL61200 | 0.77 | ANPEP (0.43) | ANPEPRNPEPDNPEPFNTAFNTB | |
| SCHEMBL28194148 | 0.77 | ANPEP (0.42) | ANPEPRNPEPDNPEPKRASFNTA | |
| SCHEMBL7027416 | 0.76 | FNTA (0.33) | ANPEPRNPEPDNPEPKRASMARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 759 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11519923-B2 | Analyte detection system and method | SIEMENS HEALTHINEERS NEDERLAND B.V. (NL) | 2022-12-06 | — | — | US | claimed |
| CN-109328302-B | Analyte detection systems and methods | 西门子医疗系统荷兰有限公司 | 2022-06-07 | — | — | CN | claimed |
| EP-3497445-B1 | METHODS FOR MICROPATTERNING AND MICROPATTERNED DEVICES | IST AUSTRIA INSTITUTE OF SCIENCE AND TECH AUSTRIA (AT) | 2022-02-16 | — | — | EP | claimed |
| US-20200182894-A1 | ANALYTE DETECTION SYSTEM AND METHOD | SIEMENS HEALTHINEERS NEDERLAND B.V. (NL) | 2020-06-11 | — | — | US | claimed |
| EP-3282254-B1 | METHOD OF PRODUCING A DEVICE FOR GUIDED CELL ACTIVATION | IST AUSTRIA INSTITUTE OF SCIENCE AND TECH AUSTRIA (AT) | 2019-07-31 | — | — | EP | claimed |
| US-20190170744-A1 | MICROPATTERNING ASSEMBLY, METHODS FOR MICROPATTERNING, AND MICROPATTERNED DEVICES | IST AUSTRIA - INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA (AT) | 2019-06-06 | — | — | US | claimed |
| EP-3472616-A1 | ANALYTE DETECTION SYSTEM AND METHOD | Koninklijke Philips N.V. (NL) | 2019-04-24 | — | — | EP | claimed |
| CN-109328302-A | Analyte detection system and method | 皇家飞利浦有限公司 | 2019-02-12 | — | — | CN | claimed |
| EP-3282254-A1 | DEVICE FOR GUIDED CELL ACTIVATION | IST Austria (Institute of Science and Technology Austria) (AT) | 2018-02-14 | — | — | EP | claimed |
| WO-2017220483-A1 | ANALYTE DETECTION SYSTEM AND METHOD | KONINKLIJKE PHILIPS N.V. (NL) | 2017-12-28 | — | — | WO | claimed |
| WO-2006089106-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2006-08-24 | — | — | WO | claimed |
| US-20050054614-A1 | Methods of inhibiting leukocyte accumulation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-10 | — | — | US | claimed |
| WO-2005016349-A1 | METHODS OF INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-6696276-B2 | Vasopermeability-enhancing conjugates | UNIVERSITY OF SOUTHERN CALIFORNIA | 2004-02-24 | — | — | US | claimed |
| US-20030113872-A1 | Vasopermeability-enhancing conjugates | EPSTEIN ALAN L (US) | 2003-06-19 | — | — | US | claimed |
| US-6524823-B2 | Vasopermeability-enhancing conjugates | THE UNIVERSITY OF SOUTHERN CALIFORNIA | 2003-02-25 | — | — | US | claimed |
| US-6416965-B2 | COMBINING COMPOUND WITH PHOSPHOLIPASE D(PLD), TREATING MIXTURE WITH PHOSPHATIDYLCHOLINE SO THAT CLEAVAGE REACTION BETWEEN PHOSPHATIDYLCHOLINE AND PLD CAN OCCUR, RESULTING IN GENERATION OF PHOSPHATIDIC ACID AND CHOLINE, EVALUATING AMOUNT OF CHOLINE | BRIGHAM AND WOMEN'S HOSPITAL | 2002-07-09 | — | — | US | claimed |
| US-20020068328-A1 | Vasopermeability-enhancing conjugates | UNIVERSITY OF SOUTHERN CALIFORNIA, THE | 2002-06-06 | — | — | US | claimed |
| US-6007817-A | Vasopermeability enhancing immunoconjugates | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1999-12-28 | — | — | US | claimed |
| EP-0438497-B1 | VASOPERMEABILITY-ENHANCING CONJUGATES | UNIV SOUTHERN CALIFORNIA (US) | 1996-03-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054614-A1 | Methods of inhibiting leukocyte accumulation | PI4KB, PIK3CD, PIK3CA | ANPEP 2747/4885RNPEP 2246/4885DNPEP 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.